Sickle cell disease reshapes lives—millions diagnosed yearly with genetic roots

Sickle cell disease affects millions globally, with around 300,000 newborns diagnosed each year. The condition arises from a genetic mutation in the HBB gene, altering red blood cell shape and function. While the highest prevalence outside the U.S. is found in sub-Saharan Africa, India, and the Caribbean, the disease also impacts between 1 million and 3 million Americans—particularly within the Black population.

The disease and sickle cell trait both stem from changes in the same gene. Those with the trait inherit one mutated HBB gene, while those with the disease inherit two. Unlike the trait, which cannot progress into the disease, sickle cell disease causes red blood cells to become rigid and sickle-shaped. These abnormal cells can lead to symptoms such as chronic pain, fatigue, and swelling, with severity varying widely among individuals.

Over 100 million people worldwide carry the sickle cell trait. While most experience no major health issues, rare complications may arise during extreme physical exertion or severe dehydration. Genetic testing now helps families assess the risk of passing the trait or disease to future children.

Advances in treatment have improved life expectancy and reduced complications for those living with sickle cell disease. New therapies aim to manage pain crises and enhance long-term quality of life.

Sickle cell disease remains a significant global health challenge, with high diagnosis rates in newborns each year. Ongoing research and improved treatments continue to change outcomes for patients. Meanwhile, genetic testing offers clearer insights into inheritance risks for families affected by the condition.